# US 2021/0340531 A1 · Compositions and Methods for Inhibiting Intermediate Filament Tetramerization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340531 A1
- Document ID: US20210340531A1
- Status: Published application
- Kind: A1
- Application number: 17/283,405
- Filed: 2019-10-08
- Published: 2021-11-04
- Earliest claimed: 2018-10-08
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Christopher Bunick; Sherif Eldirany; Minh Ho
- Web page: https://patentgrep.com/patent/US20210340531A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- G01N 33/575: for cancer
- A61K 38/1709: {from mammals}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61P 27/00: Drugs for disorders of the senses
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/4741: {Keratin; Cytokeratin}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- G01N 2333/4742: Keratin; Cytokeratin
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2800/7047: Fibrils-Filaments-Plaque formation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compositions and methods for inhibiting intermediate filament tetramerization and formation.

## Claims

### Claim 1 (depends on 22)

A method for inhibiting intermediate filament formation, the method comprising administering the composition of claim 22.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor is selected from a protein, a peptide, a peptidomemetic, an antibody, a small molecule chemical compound, CRISPR/Cas9, a nucleic acid, and a vector.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the method inhibits vimentin intermediate filament formation, wherein first intermediate filament dimer is a first vimentin homodimer, and the second intermediate filament dimer is a second vimentin homodimer.

### Claim 5 (depends on 4)

The method of claim 4, wherein the inhibitor is a peptide derived from the vimentin homodimer anchoring knob domain.

### Claim 6 (depends on 5)

The method of claim 5, wherein the peptide comprises a sequence at least 90% homologous to a sequence selected from the group consisting of SEQ ID NO:36-67.

### Claim 7 (depends on 4)

The method of claim 4, wherein the inhibitor is CRISPR/Cas9 and the CRISPR/Cas9 comprises a guide RNA targeted to induce at least one mutation in the vimentin homodimer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the least one mutation in the vimentin homodimer is at a vimentin residue selected from the group consisting of F233 and L237.

### Claim 9 (depends on 4)

The method of claim 4, wherein the inhibitor prevents or reduces vimentin tetramerization.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method inhibits keratin intermediate filament formation, wherein first intermediate filament dimer is a first K1/K10 heterodimer, and the second intermediate filament dimer is a second K1/K10 heterodimer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inhibitor is a peptide derived from the K1/K10 anchoring knob domain.

### Claim 12 (depends on 11)

The method of claim 11, wherein the peptide comprises K1 residues F314 and L318.

### Claim 13 (depends on 11)

The method of claim 11, wherein the peptide comprises a sequence at least 90% homologous to a sequence selected from the group consisting of SEQ ID NO:3-34.

### Claim 14 (depends on 10)

The method of claim 10, wherein the inhibitor is CRISPR/Cas9 and the CRISPR/Cas9 comprises a guide RNA targeted to induce at least one mutation in the K1/K10 heterodimer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the least one mutation in the K1/K10 heterodimer is at a K1 residue selected from the group consisting of Y230, F231, F234, F314 and L318.

### Claim 16 (depends on 10)

The method of claim 10, wherein the inhibitor prevents or reduces K1/K10 tetramerization.

### Claim 17 (depends on 22)

A method of treating a disease or disorder associated with intermediate filament formation, the method comprising administering the composition of claim 22.

### Claim 18 (depends on 17)

The method of claim 17, wherein the method comprises administering an inhibitor of the interaction between the anchoring knob domain of a first K1/K10 heterodimer and the hydrophobic pocket of a second K1/K10 heterodimer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease or disorder is selected from the group consisting of cancer, skin blistering and fragility disorders, disorders of keratinization, eye disease, scarring, and liver disease.

### Claim 20 (depends on 17)

The method of claim 17, wherein the method comprises administering an inhibitor of the interaction between the anchoring knob domain of a first vimentin homodimer and the hydrophobic pocket of a second vimentin homodimer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the disease or disorder is selected from the group consisting of lung injury, scarring, human immunodeficiency virus (HIV), cancer, and cataracts.

### Claim 22

A composition for inhibiting intermediate filament formation, the composition comprising an inhibitor of the interaction between the anchoring knob domain of a first intermediate filament dimer and the hydrophobic pocket of a second intermediate filament dimer.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the inhibitor inhibits the interaction between the anchoring knob domain of a first vimentin homodimer and the hydrophobic pocket of a second vimentin homodimer.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the inhibitor is a peptide comprising a sequence at least 90% homologous to one of SEQ ID NOs:36-67 or a nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence at least 90% homologous to one of SEQ ID NOs:36-67.

### Claim 25 (depends on 22)

The composition of claim 22, wherein the inhibitor inhibits the interaction between the anchoring knob domain of a first K1/K10 heterodimer and the hydrophobic pocket of a second K1/K10 heterodimer.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the inhibitor is a peptide comprising a sequence at least 90% homologous to one of SEQ ID NOs:3-34 or a nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence at least 90% homologous to one of SEQ ID NOs:3-34.

### Claim 27

A method of screening a library of compounds to provide an inhibitor of intermediate filament formation, the method comprising:
(a) contacting a hydrophobic pocket domain of an intermediate filament dimer;
(b) measuring a binding of the at least one compound to the hydrophobic pocket;
(c) comparing the binding of the at least one compound to the hydrophobic pocket, with a binding of a comparator control to the hydrophobic pocket; and
(d) selecting the at least one compound from the library when the binding of the at least one compound to the hydrophobic pocket, is increased at a statistically significant amount when compared with the binding of the comparator control to the hydrophobic pocket.

### Claim 28 (depends on 27)

A compound selected from a pool of modulators of inhibitor intermediate filament tetramer formation, wherein the pool is identified by the method of claim 27.

### Claim 29

A method of screening a library of compounds to provide an inhibitor of intermediate filament tetramer formation, the method comprising:
(a) mixing a first intermediate filament dimer with at least one compound from the library to form a mixture;
(b) adding a second intermediate filament dimer to the mixture;
(c) measuring intermediate filament formation;
(d) comparing the tetramer formation to a comparator control; and
(e) selecting the at least one compound from the library when the tetramer formation is altered at a statistically significant amount when compared with the tetramer formation of the comparator control.

### Claim 30 (depends on 29)

A compound selected from a pool of modulators of inhibitor intermediate filament tetramer formation, wherein the pool is identified by the method of claim 29.
